Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Breast Cancer

  Free Subscription

Articles published in Mod Pathol

Retrieve available abstracts of 13 articles:
HTML format
Text format

Single Articles

    August 2019
  1. LANJEWAR S, Patil P, Fineberg S
    Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Mod Pathol. 2019 Aug 5. pii: 10.1038/s41379-019-0326.
    PubMed     Text format     Abstract available

    June 2019
  2. LOBO J, Petronilho S, Newell AH, Coach J, et al
    E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.
    Mod Pathol. 2019 Jun 23. pii: 10.1038/s41379-019-0294.
    PubMed     Text format     Abstract available

    April 2019
  3. ABUBAKAR M, Figueroa J, Ali HR, Blows F, et al
    Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
    Mod Pathol. 2019 Apr 11. pii: 10.1038/s41379-019-0270.
    PubMed     Text format     Abstract available

    October 2018
  4. CLARK BZ, Onisko A, Assylbekova B, Li X, et al
    Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.
    Mod Pathol. 2018 Oct 16. pii: 10.1038/s41379-018-0153.
    PubMed     Text format     Abstract available

    August 2018
  5. ROSS DS, Zehir A, Brogi E, Konno F, et al
    Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
    Mod Pathol. 2018 Aug 29. pii: 10.1038/s41379-018-0116.
    PubMed     Text format     Abstract available

  6. LEE M, Heo SH, Song IH, Rajayi H, et al
    Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis.
    Mod Pathol. 2018 Aug 28. pii: 10.1038/s41379-018-0113.
    PubMed     Text format     Abstract available

  7. RIMM DL, Leung SCY, McShane LM, Bai Y, et al
    An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.
    Mod Pathol. 2018 Aug 24. pii: 10.1038/s41379-018-0109.
    PubMed     Text format     Abstract available

    June 2018
  8. SONBUL SN, Aleskandarany MA, Kurozumi S, Joseph C, et al
    Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.
    Mod Pathol. 2018 Jun 28. pii: 10.1038/s41379-018-0092.
    PubMed     Text format     Abstract available

    May 2018
  9. DILL EA, Dillon PM, Bullock TN, Mills AM, et al
    IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Mod Pathol. 2018 May 25. pii: 10.1038/s41379-018-0061.
    PubMed     Text format     Abstract available

    April 2018
    Expanding definitions of HER2 positivity.
    Mod Pathol. 2018;31:685.
    PubMed     Text format    

  11. STEWART RL, Gulbahce EH, Geiersbach KB, Downs-Kelly E, et al
    Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'.
    Mod Pathol. 2018;31:686.
    PubMed     Text format    

    October 2017
  12. ADAMS TA, Vail PJ, Ruiz A, Mollaee M, et al
    Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

  13. SANCHEZ-MUNOZ A, Vicioso L, Santonja A, Alvarez M, et al
    Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Mod Pathol. 2017 Oct 6. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.